Sophia Genetics SA (SOPH) News
Filter SOPH News Items
SOPH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SOPH News From Around the Web
Below are the latest news stories about SOPHIA GENETICS SA that investors may wish to consider to help them evaluate SOPH as an investment opportunity.
US Penny Stocks To Watch In December 2024As the U.S. stock market enters December 2024, investors are witnessing record highs for the S&P 500 and Nasdaq Composite, marking a robust period of growth following significant gains in November. Amid this backdrop, penny stocks—often associated with smaller or newer companies—remain an intriguing investment option due to their potential for substantial growth at lower price points. While traditionally considered speculative, those penny stocks with strong financials can offer unique... |
SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, announced the global launch of MSK-IMPACT® powered with SOPHiA DDM™ today from the Association for Molecular Pathology (AMP) Annual Meeting. This innovative solution provides organizations worldwide with the opportunity to benefit from Memorial Sloan Kettering Cancer Center (MSK)'s best-in-class comprehensive genomic profiling (CGP) application on the SOPHiA DDM™ Platform with high accuracy and e |
Earnings Release: Here's Why Analysts Cut Their SOPHiA GENETICS SA (NASDAQ:SOPH) Price Target To US$6.00SOPHiA GENETICS SA ( NASDAQ:SOPH ) shareholders are probably feeling a little disappointed, since its shares fell 5.0... |
SOPHiA GENETICS Faces Financial Challenges Amid LossesSOPHiA GENETICS (SOPH) has released an update. SOPHiA GENETICS reported a revenue of $15.8 million for the third quarter of 2024, slightly down from $16.3 million in the same period in 2023. Despite a gross profit of $10.7 million, the company incurred a significant operating loss of $15.4 million, largely due to high research, selling, and administrative costs. This financial performance may pose challenges for investors considering the company’s stock, as losses before income taxes amounted to |
SOPHiA GENETICS Third Quarter 2024 Earnings: Misses ExpectationsSOPHiA GENETICS ( NASDAQ:SOPH ) Third Quarter 2024 Results Key Financial Results Revenue: US$15.9m (down 2.8% from 3Q... |
Sophia Genetics SA (SOPH) Q3 2024 Earnings Call Highlights: Navigating Challenges with ...Sophia Genetics SA (SOPH) reports a mixed quarter with improved operational efficiency and strategic advancements amid revenue challenges. |
Q3 2024 Sophia Genetics SA Earnings CallQ3 2024 Sophia Genetics SA Earnings Call |
SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial OfficerSOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO. |
SOPHiA GENETICS Reports Third Quarter 2024 ResultsSOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the third quarter ended September 30, 2024. |
SOPHiA GENETICS SA (SOPH): A Bull Case TheoryWe came across a bullish thesis on SOPHiA GENETICS SA (SOPH) on Two Natural Cap’s Substack by Two Natural Capital. In this article, we will summarize the bulls’ thesis on SOPH. SOPHiA GENETICS SA (SOPH)’s share was trading at $3.64 as of Nov 1st. Sophia Genetics is carving out a unique niche in the crowded cancer screening […] |